Company intelligence / Profile preview
Jazz Pharmaceuticals plc
Dublin, Irelandjazzpharma.com ↗
- Ownership
- Public · JAZZ
- Employees
- ~2800
- Development stage
- Other
01
Overview
Jazz Pharmaceuticals has multiple FDA-approved products on the market including Xyrem, Xywav, Vyxeos, Defitelio, and others. The company has a diverse portfolio of marketed medicines for sleep disorders and epilepsy, and a growing portfolio of cancer treatments.
- Therapeutic areas
- OncologyPsychiatryNeurology
- Modalities
- Small moleculesbispecific antibodies
- Industry
- Biotech
02
Drug pipeline
78 assets77 more assets in the full pipeline.
03
Partnerships
Zymeworks Inc.Werewolf Therapeutics, Inc.Sumitomo Pharma Co., Ltd.Redx PharmaCodiak BioSciencesLife Science Cares
04
Financials
- Market cap
- $14.6B
- Total revenue
- $4.3B
- Enterprise value
- $17.4B
Beyond the preview
Go deeper on Jazz Pharmaceuticals plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jazz Pharmaceuticals plc.